Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, Agabio R, Colombo G, Gessa GL, Gasbarrini G (2002) Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 37(5):504–508

PubMed  CAS  Google Scholar 

Addolorato G, Leggio L, Ferrulli A, Cardone S, Bedogni G, Caputo F, Gasbarrini G, Landolfi R (2011) Dose-response effect of Baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol 46(3):312–317

PubMed  CAS  Google Scholar 

Akbar M, Egli M, Cho YE, Song BJ, Noronha A (2018) Medications for alcohol use disorders: an overview. Pharmacol Ther 185:64–85

PubMed  CAS  Google Scholar 

American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. Author, Washington, DC

Google Scholar 

Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM et al (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence. The combine study: a randomized controlled trial. JAMA 295:2003–2017

PubMed  CAS  Google Scholar 

Anton RF, Oroszi G, O’Malley S, Couper D, Swift R, Pettinati H, Goldman D (2008) An evaluation of µ-opioid receptor (OPRM1) as a predictor of Naltrexone response in the treatment of alcohol dependence: results from the combined pharmacotherapies and behavioral interventions for alcohol dependence (COMBINE) study. Arch Gen Psychiatry 65(2):135–144

PubMed  PubMed Central  CAS  Google Scholar 

Beck AT, Steer RA, Brown GK (1996) Beck depression inventory-II. San Antonio 78(2):490–498

Google Scholar 

Beck A, Wustenberg T, Genauck A, Wrase J, Schlagenhauf F, Smolka MN, Mann K, Heinz A (2012) Effect of brain structure, brain function, and brain connectivity on relapse in alcohol-dependent patients. Arch Gen Psychiatry 69:842–852

PubMed  Google Scholar 

Beck A, Pelz P, Lorenz RC, Charlet K, Geisel O, Heinz A, Müller CA (2018) Effects of high-dose Baclofen on cue reactivity in alcohol dependence: a randomized, placebo-controlled pharmaco-fMRI study. Eur Neuropsychopharmacol 28(11):1206–1216

PubMed  CAS  Google Scholar 

Beraha EM, Salemink E, Goudriaan AE, Bakker A, de Jong D, Smits N, Wiers RW (2016) Efficacy and safety of high-dose Baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. Eur Neuropsychopharmacol 26(12):1950–1959

PubMed  CAS  Google Scholar 

Campanella S, Schroder E, Kajosch H, Hanak C, Veeser J, Amiot M, Kornreich C (2020) Neurophysiological markers of cue reactivity and Inhibition subtend a three-month period of complete alcohol abstinence. Clin Neurophysiol 131(2):555–565

PubMed  Google Scholar 

Campanella S (2021) Use of cognitive event-related potentials in the management of psychiatric disorders: towards an individual follow-up and multi-component clinical approach. World J Psychiatry 11(5):153

PubMed  PubMed Central  Google Scholar 

Campanella S, Bruyer R, Froidbise S, Rossignol M, Joassin F, Kornreich C et al (2010) Is two better than one? A cross-modal oddball paradigm reveals greater sensitivity of the P300 to emotional face-voice associations. Clin Neurophysiol 121(11):1855–1862

PubMed  Google Scholar 

Campanella S, Delle-Vigne D, Kornreich C, Verbanck P (2012) Greater sensitivity of the P300 component to bimodal stimulation in an event-related potentials oddball task. Clin Neurophysiol 123(5):937–946

PubMed  Google Scholar 

Campanella S, Schroder E, Kajosch H, Noel X, Kornreich C (2019) Why cognitive event-related potentials (ERPs) should have a role in the management of alcohol disorders. Neurosci Biobehavioral Reviews 106:234–244

Google Scholar 

Carver CS, White TL (1994) Behavioral inhibition, behavioral activation, and affective responses to impending reward and punishment: the BIS/BAS scales. J Personal Soc Psychol 67(2):319

Google Scholar 

Chick J, Howlett H, Morgan MY, Ritson B (2000) United Kingdom multicentre acamprosate study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 35(2):176–187

PubMed  CAS  Google Scholar 

Cofresí RU, Piasecki TM, Hajcak G, Bartholow BD (2022) Internal consistency and test–retest reliability of the P3 event-related potential (ERP) elicited by alcoholic and non‐alcoholic beverage pictures. Psychophysiology 59(2):13967

Google Scholar 

Courtney KE, Schacht JP, Hutchison K, Roche DJ, Ray LA (2016) Neural substrates of cue reactivity: association with treatment outcomes and relapse. Addict Biol 21(1):3–22

PubMed  Google Scholar 

Cox WM, Yeates GN, Regan CM (1999) Effects of alcohol cues on cognitive processing in heavy and light drinkers. Drug Alcohol Depend 55(1–2):85–89

PubMed  CAS  Google Scholar 

De Beaurepaire R (2018) A review of the potential mechanisms of action of Baclofen in alcohol use disorder. Front Psychiatry 9:506

PubMed  PubMed Central  Google Scholar 

De Beaurepaire R, Sinclair JM, Heydtmann M, Addolorato G, Aubin HJ, Beraha EM, Agabio R (2019) The use of Baclofen as a treatment for alcohol use disorder: a clinical practice perspective. Front Psychiatry 9:708

PubMed  PubMed Central  Google Scholar 

Dubuson M, Kornreich C, Vanderhasselt MA, Baeken C, Wyckmans F, Dousset C, Noël X (2021) Transcranial direct current stimulation combined with alcohol cue inhibitory control training reduces the risk of early alcohol relapse: a randomized placebo-controlled clinical trial. Brain Stimul 14(6):1531–1543

PubMed  Google Scholar 

Finney JW, Hahn AC, Moos RH (1996) The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. Addiction 91:1773–1796

PubMed  CAS  Google Scholar 

Flaudias V, Brousse G, de Chazeron I, Planche F, Brun J, Llorca PM (2013) Treatment in hospital for alcohol-dependent patients decreases attentional bias. Neuropsychiatr Dis Treat 773–779

Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA (2010) Efficacy and safety of Baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcoholism Clin Experimental Res 34(11):1849–1857

CAS  Google Scholar 

Grüsser SM, Wrase J, Klein S, Hermann D, Smolka MN, Ruf M, Weber-Fahr W, Flor H, Mann K, Braus DF, Heinz A (2004) Cue-induced activation of the striatum and medial prefrontal cortex is associated with subsequent relapse in abstinent alcoholics. Psychopharmacology 175:296–302

PubMed  Google Scholar 

Guglielmo R, Kobylinska L, de Filippis R (2022) Topiramate, naltrexone, and acamprosate in the treatment of alcohol use disorders. NeuroPsychopharmacotherapy. Springer International Publishing, Cham, pp 2535–2550

Google Scholar 

Hammarberg A, Jayaram-Lindström N, Beck O, Franck J, Reid MS (2009) The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. Psychopharmacology 205:53–62

PubMed  CAS  Google Scholar 

Hanak C (2018) Prise En charge du sevrage alcoolique. Rev Med Bruxelles 39(4):241–245

CAS  Google Scholar 

Harris BR, Gibson DA, Prendergast MA, Blanchard JA, Holley RC, Hart SR, Littleton JM (2003) The neurotoxicity induced by ethanol withdrawal in mature organotypic hippocampal slices might involve cross-talk between metabotropic glutamate type 5 receptors and N‐methyl‐D‐aspartate receptors. Alcoholism: Clin Experimental Res 27(11):1724–1735

CAS  Google Scholar 

Hogue A, Dauber S, Morgenstern J (2010) Validation of a contemplation ladder in an adult substance use disorder sample. Psychol Addict Behav 24(1):137

PubMed  PubMed Central  Google Scholar 

Ingels A, Fabry L, Hanak C, Hanard F, Kajosch H, Kornreich C, Campanella S (2022) Using cognitive event-related potentials in the management of alcohol use disorder: towards an individual approach. Archives Clin Med Case Rep 6(6):772–775

Google Scholar 

Johnson BA (2008) Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 75(1):34–56

PubMed  CAS  Google Scholar 

Kaplan RF, Cooney NL, Baker LH, Gillespie RA, Meyer RE, Pomerleau OF (1985) Reactivity to alcohol-related cues: physiological and subjective responses in alcoholics and nonproblem drinkers. J Stud Alcohol 46(4):267–272

PubMed  CAS  Google Scholar 

Katz JL, Higgins ST (2003) The validity of the reinstatement model of craving and relapse to drug use. Psychopharmacology 168:21–30

PubMed  CAS  Google Scholar 

Kavanagh DJ, Statham DJ, Feeney GFX, Young RM, May J, Andrade J, Connor JP (2013) Measurement of alcohol craving. Addict Behav 38:1572–1584

PubMed  Google Scholar 

Kenna GA, Lomastro TL, Schiesl A, Leggio L, Swift RM (2009) Review of topiramate: an antiepileptic for the treatment of alcohol dependence. Curr Drug Abuse Rev 2:135–142

PubMed  CAS  Google Scholar 

Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Wiedemann K (2003) Comparing and combining Naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 60(1):92–99

PubMed  CAS  Google Scholar 

Kohen CB, Cofresí RU, Piasecki TM, Bartholow BD (2024) Predictive utility of the P3 event-related potential (ERP) response to alcohol cues for ecologically assessed alcohol craving and use. Addict Biol 29(2):e13368. https://doi.org/10.1111/adb.13368

PubMed  PubMed Central  Google Scholar 

Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345(24):1734–1739

PubMed  CAS  Google Scholar 

Langosch JM, Spiegelhalder K, Jahnke K, Feige B, Regen W, Kiemen A, Olbrich HM (2012) The impact of acamprosate on cue reactivity in alcohol dependent individuals: a functional magnetic resonance imaging study. J Clin Psychopharmacol 32(5):661–665

Pub